Data
Challenge

CONGRATULATIONS TO THE WINNERS OF THE GNPC DATA CHALLENGE

About the GNPC Data Challenge

We're backing accelerated biomarker discovery in Alzheimer's disease and related dementias.

The Global Neurodegeneration Proteomics Consortium (GNPC) is analyzing the largest disease-specific proteomics dataset ever assembled, consisting of over 250 million protein measurements.

Our goal is to use the GNPC v1 Harmonized Dataset to generate insights that could improve detection, prognosis, and treatment pathways. All data analysis is being conducted using AD Workbench.

Explore GNPC Dataset Sign Up for AD Workbench

Meet the Winners of the GNPC Data Challenge

Researchers from across the globe submitted projects using the GNPC v1 Harmonized Dataset through AD Workbench to answer seven priority research questions. The winning projects selected across six of those questions are advancing what we know about detection, progression, prevention, and subtyping in Alzheimer's disease and related dementias.

Priority Research Questions and Winners

Question 1: Protein dynamics over time: Do longitudinal protein changes track healthy aging and disease progression, including preclinical to post-diagnosis AD?

First place: Wenyu Zhou, Teal Rise, Inc
Project: Protein Dynamics Over Time: Tracking Healthy Aging and Disease Progression from Preclinical to Post-Diagnosis AD
Second place: Juan Shu, University of Pennsylvania
Project: Dynamic Protein Profiles and Aging Trajectories in Alzheimer’s Disease

Question 2: Plasma markers & progression: Do plasma changes influence/reflect progression speed? Any promising therapeutic targets?

First place: Junyoung Park, Stanford University
Project: Uncovering Causal Drivers of Alzheimer’s Disease Progression Rate through Longitudinal Plasma Proteomics and Mendelian Randomization
Second place: Evan Boyle, Octave Bioscience
Project: Levodopa-Stratified Plasma Proteomics for Parkinson’s Disease Progression

Question 3: Prognostic markers: Can we predict cognitive decline and neurodegeneration?

First place: Andre Altmann, University College London
Project: Data-Driven CSF Proteomic Event-Based Modeling for Alzheimer’s Disease Staging
Second place: Felix Breach, University of Cambridge
Project: AI-omics Markers for Precise Dementia Prediction and Prognosis

Question 4: Subtyping AD: Can biomarker patterns define meaningful clinical subtypes?

First place: Yann Le Guen, Stanford University
Project: Plasma Proteomics Reveals Continuous, Region-Specific Vulnerability Axes in Alzheimer’s Disease

Question 5: Delaying onset: Can proteomics inform prevention?

First place: Andrew Phipps, University of Tasmania
Project: Can Proteomics Inform Prevention? Modifiable Risk and Molecular Signatures
Second place: Yann Le Guen, Stanford University
Project: Proteomic Signatures of APOE*ε4 Resilience Reveal Causal Pathways That Delay Alzheimer’s Disease Onset

Question 6: How do the cellular origins and biological pathways of plasma proteins reflect and influence Alzheimer’s disease processes, and what insights could this provide for developing diagnostic or therapeutic strategies?

First place: Kuan-lin Huang, Icahn School of Medicine at Mount Sinai
Project: TRACE: Tracing Cellular Origins of Alzheimer’s Disease Circulating Biomarkers

Read News Article

Stay tuned for more information about the winners' publications and posters.

View Rules & Guidelines

Partners

AnswerALS

Longitudinal clinical and omics data.

GAP Bio-Hermes

Cross-platform AD diagnostics (blood biomarkers, digital tests, cognitive assessments).

Data Challenge